A Randomized, Double-blind, Placebo-Controlled, Four- Part Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ONO-5788 in Healthy Adult Volunteers
Phase of Trial: Phase I
Latest Information Update: 07 Jun 2019
Price : $35 *
At a glance
- Drugs ONO-5788 (Primary) ; Octreotide
- Indications Acromegaly
- Focus Adverse reactions; First in man
- Sponsors Ono Pharmaceutical
- 03 Jun 2019 Status changed from recruiting to discontinued.
- 18 Mar 2019 Interim results (n=48) assessing safety, tolerability and pharmacokinetics presented at the 101st Annual Meeting of the Endocrine Society.
- 03 Jan 2019 Planned End Date changed from 25 Jan 2019 to 25 Apr 2019.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History